CAJ | 학술논문

肺癌目前位于全世界癌症死因的首位,约占全部恶性肿瘤的19％.每年约有超过100万人死于肺癌,严重威胁着人类的健康和生命.其中,非小细胞肺癌约占80％～85％.研究显示环氧化酶-2(cyclooxygenase-2,COX-2)在非小细胞肺癌组织中表达上调,并且与肿瘤细胞的增殖、侵袭和远处转移有关.近年来COX-2抑制剂在非小细胞肺癌治疗中的作用日益受到关注.特异性COX-2抑制剂(尼美舒利、塞来昔布、罗非昔布、NS398等)和非特异性COX-2抑制剂(吲哚美辛、布洛芬等)对非小细胞肺癌均有抗肿瘤作用,可增加非小细胞肺癌化疗及放疗的敏感性.实验研究表明COX-2抑制剂可抑制非小细胞肺癌细胞的增殖,诱导细胞的凋亡,抑制肿瘤新生血管的生成,抑制肿瘤远处转移等.国外临床研究表明COX-2抑制剂可提高化疗药物的临床疗效,并减弱化疗不良反应.COX-2抑制剂显著的抗肿瘤作用为非小细胞肺癌的治疗带来了新的曙光.
폐암목전위우전세계암증사인적수위,약점전부악성종류적19％.매년약유초과100만인사우폐암,엄중위협착인류적건강화생명.기중,비소세포폐암약점80％～85％.연구현시배양화매-2(cyclooxygenase-2,COX-2)재비소세포폐암조직중표체상조,병차여종류세포적증식、침습화원처전이유관.근년래COX-2억제제재비소세포폐암치료중적작용일익수도관주.특이성COX-2억제제(니미서리、새래석포、라비석포、NS398등)화비특이성COX-2억제제(신타미신、포락분등)대비소세포폐암균유항종류작용,가증가비소세포폐암화료급방료적민감성.실험연구표명COX-2억제제가억제비소세포폐암세포적증식,유도세포적조망,억제종류신생혈관적생성,억제종류원처전이등.국외림상연구표명COX-2억제제가제고화료약물적림상료효,병감약화료불량반응.COX-2억제제현저적항종류작용위비소세포폐암적치료대래료신적서광.
Lung cancer is the leading cause of cancer death in the world now,accounting for about 19％ of all malignant tumors.More than one million people die from lung cancer each year,which has been a serious threat to human health and life.Non-small cell lung cancer accounts for 80％-85 ％.Studies have shown that up-regulation of cyclooxygenase-2 (COX-2) expression in non-small cell lung cancer,which is correlated with the tumor cell proliferation,invasion,and metastasis.In recent years,the role of COX-2 inhibitors in the treatment of non-small cell lung cancer has been paid more and more attention.Both specific COX-2 inhibitors (nimesulide,celecoxib,rofecoxib,and NS398) and nonspecific COX-2 inhibitors (indomethacin,ibuprofen) have the anti-tumor effect on non-small cell lung cancer,and also can increase the sensitivity of chemotherapy and radiotherapy.Experimental studies have shown that COX-2 inhibitors may inhibit tumor cell proliferation,induce apoptosis,inhibit tumor angiogenesis and metastasis.Clinical studies abroad have shown that COX-2 inhibitors may enhance the clinical outcomes of chemotherapy,and reduce the side effects.All these have brought a new dawn for the treatment of nonsmall cell lung cancer.